Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566455 | 0.89 | EGFR (0.53) | EGFRKDRSRCKIT | |
| SCHEMBL5566432 | 0.83 | KDR (0.44) | EGFRKDRAURKAPDGFRBFLT4 | |
| SCHEMBL5561051 | 0.82 | FLT4 (0.52) | EGFRKDRSRCAURKAPDGFRB | |
| SCHEMBL5566618 | 0.80 | KDR (0.61) | EGFRKDRSRCAURKAPDGFRB | |
| SCHEMBL4380590 | 0.80 | EGFR (0.47) | EGFRKDRSRCFLT4RAF1 | |
| SCHEMBL4379772 | 0.79 | EGFR (0.49) | EGFRKDRSRCPDGFRBFLT4 | |
| SCHEMBL4373703 | 0.79 | PDE3B (0.52) | EGFRKDRAURKATEKAURKB | |
| SCHEMBL7876949 | 0.78 | KDR (0.37) | EGFRKDRAURKAPDGFRBFLT4 | |
| SCHEMBL6446706 | 0.77 | SRC (0.42) | EGFRKDRSRCKIT | |
| SCHEMBL4374170 | 0.76 | EGFR (0.51) | EGFRKDRSRCFLT4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | claimed |
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | claimed |
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | disclosed |
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | disclosed |